

SUPPLEMENTARY TABLE 1. Characteristics of participants included in estimation of pertussis vaccine effectiveness, without matching by facility (N = 428) — Alaska, May–November 2024

Characteristic	No. (%)		P-value
	Case-patients (n = 106)	Control patients (n = 322)	
Median age, yrs (IQR)	3.2 (1.1–5.3)	3.3 (1.3–4.6)	Not applicable*
Age group			
6 months–2 years	47 (44.3)	145 (45.0)	Not applicable*
3–6 years	59 (55.7)	177 (55.0)	
Sex			
Female	59 (55.7)	155 (48.1)	0.079
Male	46 (43.4)	167 (51.9)	
Race			
AI/AN	37 (34.9)	192 (59.6)	<0.001
API	3 (2.8)	11 (3.4)	
Black or African American	2 (1.9)	4 (1.2)	
Other/multiracial	19 (17.9)	52 (16.1)	
White	45 (42.5)	63 (19.6)	
Ethnicity			
Hispanic or Latino	0 (0)	13 (4.0)	0.029
Not Hispanic or Latino	68 (64.2)	220 (68.3)	
Unknown	38 (35.8)	89 (27.6)	
Pertussis vaccination status			
Fully vaccinated [†]	24 (22.6)	248 (77.0)	<0.001
Partially vaccinated [§]	12 (11.3)	38 (11.8)	
Unvaccinated [¶]	70 (66.0)	36 (11.2)	
VFC-eligible**			
Yes	23 (21.7)	142 (44.1)	<0.001
No	13 (12.3)	141 (43.8)	
Unknown	70 (66.0)	39 (12.1)	

Abbreviations: AI/AN = American Indian/Alaska Native; API = Asian/Pacific Islander; DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; VFC = Vaccines for Children Program.

*Case- and control patients were matched on birth year and therefore no p-value was calculated.

[†] Documented receipt of ≥3 DTaP doses

[§] Documented receipt of 1 or 2 DTaP doses

[¶] No documented receipt of any DTaP dose

** [VFC](#) provides vaccines to uninsured or underinsured children.